Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Becker, B. N.
Right arrow Articles by Hakim, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Becker, B. N.
Right arrow Articles by Hakim, R.

Journal of the American Society of Nephrology, Vol 5, 1746-1750, Copyright © 1995 by American Society of Nephrology

REGULAR ARTICLES

Intravenous immune globulin in the treatment of patients with systemic lupus erythematosus and end-stage renal disease

BN Becker, H Fuchs and R Hakim
Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232-2372, USA.

Intravenous immune globulin (IVIg) has been advocated as efficacious therapy for a variety of disorders including idiopathic thrombocytopenic purpura and Kawasaki disease. Several reports have also documented the effectiveness of IVIg in systemic lupus erythematosus (SLE). Two patients with symptomatic SLE and ESRD were treated with IVIg. Both patients tolerated IVIg administration well and demonstrated clinical and serologic improvement. Both individuals also experienced a transient decline in serum albumin concentration with IVIg treatment. The mechanisms by which IVIg might have effected improvement in these patients are varied and are likely related to the immunomodulatory actions of IVIg. The reversible change in albumin concentration seen in these individuals may be secondary to abrupt alterations in oncotic homeostasis. Despite this unusual effect, the documented improvement in these patients suggests that IVIg therapy may be of benefit in patients with active SLE and ESRD. Further studies are warranted to examine the mechanisms by which IVIg may exert its therapeutic effect.


This article has been cited by other articles:


Home page
 LupusHome page
L Rauova, J Lukac, Y Levy, J Rovensky, and Y Shoenfeld
High-dose intravenous immunoglobulins for lupus nephritis -- a salvage immunomodulation
Lupus, March 1, 2001; 10(3): 209 - 213.
[Abstract] [PDF]

Home page
 LupusHome page
Y. Levy, Y. Sherer, A. Ahmed, P. Langevitz, J. George, F. Fabbrizzi, J. Terryberry, M. Meissner, M. Lorber, J. B Peter, et al.
A study of 20 SLE patients with intravenous immunoglobulin clinical and serologic response
Lupus, November 1, 1999; 8(9): 705 - 712.
[Abstract] [PDF]

Home page
 LupusHome page
Y Sherer, P Langevitz, Y Levy, F Fabrizzi, and Y Shoenfeld
Treatment of chronic bilateral pleural effusions with intravenous immunoglobulin and cyclosporin
Lupus, May 1, 1999; 8(4): 324 - 327.
[Abstract] [PDF]

Home page
 LupusHome page
A. Aharon, Y. Levy, Y. Bar-Dayan, A. Afek, G. Zandman-Goddard, Y. Skurnik, F. Fabrrizzi, and Y. Shoenfeld
Successful treatment of early secondary myelofibrosis in SLE with IVIG
Lupus, January 1, 1997; 6(4): 408 - 411.
[Abstract] [PDF]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673